Inulin as a Clinical Therapeutic Intervention in Metabolic Associated Fatty Liver Disease. (1st November 2022)

• Record Type: Journal Article
• Authors: Barbero-Becerra, Varenka; Juárez-Hernández, Eva; Chávez-Tapia, Norberto C; Uribe, Misael
• Is Part Of: Food reviews international. Volume 38(2022)Supplement 1
• Page Start: 336
• Page End: 348
• Publication Date: 2022-11-01
• Subjects: Liver -- immunonutrition -- carbohydrates -- metabolic syndrome; 641
• DOI: 10.1080/87559129.2020.1867997
• Languages: English
• ISSNs: 8755-9129

Abstract

ABSTRACT: Inulin is a prebiotic which is selectively fermented by specific gut microbiota and its chemical structure seems to condition its effect on the host. Interestingly, inulin presents a lipid-lowering potential and a capacity of being a glucose-metabolism regulator, thus it could have a therapeutic role in diseases associated to metabolic syndrome such as metabolic associated fatty liver disease (MAFLD). Evidence indicates that inulin has several beneficial effects such as improvement of dysbiosis, hepatic lipogenesis and inflammation. Dose and intervention, dietary consumption, and microbiota are parameters that support the evaluation of inulin as a modulator of lipid metabolism. More studies will be required to improve the evidence of inulin as a therapeutic option in MAFLD treatment strategies.